Coherus Biosciences Signals Momentum in Earnings Call

Coherus Biosciences ((CHRS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Coherus Biosciences’ latest earnings call struck an overall upbeat tone, balancing strong commercial momentum and advancing oncology programs against near‑term revenue noise and clinical uncertainty. Management emphasized robust LOQTORZI growth, record patient starts, a fully enrolled liver cancer trial and a fresh capital raise, while cautioning that CCR8 class risk and immature data could make upcoming readouts volatile.

LOQTORZI Delivers 61% Year-Over-Year Revenue Growth

LOQTORZI net sales climbed 61% versus the prior‑year quarter to $11.8 million, underscoring strong adoption even as revenue slipped about 4.8% sequentially from $12.4 million in Q4 2025. Management framed the quarter as a solid step toward its sales ramp, with an eye on building LOQTORZI into a roughly $175 million annual product by 2028.

Record New Patient Starts Underpin Demand Momentum

New patient starts for LOQTORZI hit an all‑time high in Q1, providing a visible foundation for future revenue growth. Coherus also reported a 21% increase in both the breadth and depth of ordering accounts and noted that treatment duration continues to lengthen, supporting a multi‑quarter demand growth outlook of 10% to 15% per quarter through 2026.

CATALYST-202 HCC Trial Reaches Full Enrollment

The company has completed target accrual for CATALYST‑202, a 72‑patient, three‑arm randomized trial in first‑line hepatocellular carcinoma, with initial data expected around midyear. Prior data from the casdozokitug triplet showed an objective response rate of 38% and a complete response rate of 17%, outpacing historical benchmarks and justifying deeper biomarker work, including IL‑27 and circulating tumor DNA.

Tagmokitug Program Expands Across Multiple Tumor Types

Coherus is accelerating development of its CCR8 candidate tagmokitug, with several expansion cohorts actively enrolling, including 40‑patient head‑and‑neck and upper GI adenocarcinoma arms plus ESCC and MSS colorectal cancer cohorts. Initial data from these efforts are slated for mid‑2026 into the back half, and the first nonproprietary combo with J&J’s pasritamig in prostate cancer is expected to dose its first patient this fall.

Favorable Tagmokitug Pharmacology Amid Mixed CCR8 Landscape

Management argued that tagmokitug meets key ‘right drug’ criteria, citing linear dose‑dependent pharmacokinetics, strong target binding, clear pharmacodynamic immune effects and an acceptable safety profile, alone and with toripalimab. These features, they contend, position tagmokitug well despite uneven CCR8 results elsewhere, where some rivals have shown limited responses while others advance with promising activity.

Cost Cuts and Capital Raise Bolster Liquidity

A follow‑on equity offering added $54 million in net proceeds, bringing cash, cash equivalents and investments to $167 million at quarter‑end even after modest burn. Operating discipline is evident, with R&D from continuing operations down nearly 12% year over year to $21.5 million and SG&A down about 11% to $23.1 million, reflecting both tighter spending and the exit from biosimilars.

Seasonality and Storms Depress Q1 Revenue

LOQTORZI sales slipped modestly quarter over quarter, a move Coherus tied to typical seasonal patterns and unusually severe winter storms. The company’s analysis of an 85‑product oncology basket showed a sharper than normal Q4‑to‑Q1 decline of roughly 10% versus the usual 5%, with missed 2‑ and 3‑week dosing cycles translating into revenue that cannot be recovered later in the year.

CCR8 Class Risk Raises Stakes for Tagmokitug

Investors were reminded that CCR8 remains a high‑beta modality, with Amgen halting enrollment after only 2 responses among 77 patients even as Gilead and Sino Biopharma’s programs advance with activity. Coherus argued that success will hinge on drug pharmacology and tumor selection, but acknowledged that this mixed backdrop heightens execution and perception risk ahead of tagmokitug data.

Immature Data Could Slow Regulatory Clarity

Several midyear readouts will offer only early looks, with coverage of roughly half the planned patients in some tagmokitug cohorts and limited follow‑up. Management stressed that key regulatory endpoints such as durability and overall survival will take more time to mature, which could delay definitive conclusions and slow any formal regulatory path despite early response signals.

Cash Runway Solid but Clinical Spend a Watch Item

Coherus ended the quarter with $167 million in cash and investments, down from $172.1 million, and believes this is sufficient to fund major readouts through 2026–2027. Still, management noted that core cash burn would require roughly $175 million in annual NPC revenue to be fully covered, excluding trial costs, leaving investors focused on balancing pipeline investment against the need to preserve optionality.

Lean R&D Footprint Could Pinch if Data Are Positive

The roughly 12% year‑over‑year drop in R&D expense reflects headcount reductions and infrastructure savings, helping extend the company’s runway. However, leadership acknowledged that a leaner organization could limit speed or flexibility if multiple programs read out positively midyear and require rapid follow‑on trials or expansion into new indications.

Seasonal Weather Losses Create Permanent Volume Hit

Management underscored that treatment cycles missed during winter storms represent permanent lost doses, particularly for patients on 3‑week schedules. As a result, some of the Q1 revenue shortfall cannot simply be shifted to later quarters, reinforcing the need for continued new patient growth and account expansion to stay on track with long‑term LOQTORZI targets.

Guidance Reaffirmed as LOQTORZI Ramps and Pipeline Advances

Coherus reaffirmed its LOQTORZI trajectory, aiming for about $15 million in quarterly sales in 2026, $30 million to $35 million per quarter in 2027 and a peak near $44 million per quarter by 2028, supported by 10% to 15% average quarterly demand growth. The company reiterated that its $167 million cash balance, bolstered by the $54 million equity raise and lower operating expenses, should fund critical 2026–2027 readouts, with full‑year 2026 revenue guidance slated for August.

Coherus’ earnings call painted the picture of a company transitioning from restructuring to measured growth, with LOQTORZI’s momentum and a deep oncology pipeline offsetting weather‑related noise and CCR8 uncertainty. Investors will now watch whether midyear data validate tagmokitug’s promise and whether disciplined spending can coexist with the rapid development needed to capitalize on any positive signals.